Literature DB >> 30425108

Mapping the MHC Class I-Spliced Immunopeptidome of Cancer Cells.

Juliane Liepe1, John Sidney2, Felix K M Lorenz3, Alessandro Sette2, Michele Mishto4,5.   

Abstract

Anticancer immunotherapies demand optimal epitope targets, which could include proteasome-generated spliced peptides if tumor cells were to present them. Here, we show that spliced peptides are widely presented by MHC class I molecules of colon and breast carcinoma cell lines. The peptides derive from hot spots within antigens and enlarge the antigen coverage. Spliced peptides also represent a large number of antigens that would otherwise be neglected by patrolling T cells. These antigens tend to be long, hydrophobic, and basic. Thus, spliced peptides can be a key to identifying targets in an enlarged pool of antigens associated with cancer. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30425108     DOI: 10.1158/2326-6066.CIR-18-0424

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  27 in total

1.  Proteolytic dynamics of human 20S thymoproteasome.

Authors:  Ulrike Kuckelkorn; Sabine Stübler; Kathrin Textoris-Taube; Christiane Kilian; Agathe Niewienda; Petra Henklein; Katharina Janek; Michael P H Stumpf; Michele Mishto; Juliane Liepe
Journal:  J Biol Chem       Date:  2019-03-26       Impact factor: 5.157

Review 2.  Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Vid Leko; Steven A Rosenberg
Journal:  Cancer Cell       Date:  2020-08-20       Impact factor: 31.743

3.  The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases.

Authors:  Juan Antonio Vizcaíno; Peter Kubiniok; Kevin A Kovalchik; Qing Ma; Jérôme D Duquette; Ian Mongrain; Eric W Deutsch; Bjoern Peters; Alessandro Sette; Isabelle Sirois; Etienne Caron
Journal:  Mol Cell Proteomics       Date:  2019-11-19       Impact factor: 5.911

Review 4.  A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.

Authors:  Devin Dersh; Jaroslav Hollý; Jonathan W Yewdell
Journal:  Nat Rev Immunol       Date:  2020-08-20       Impact factor: 53.106

Review 5.  Spliced HLA-bound peptides: a Black Swan event in immunology.

Authors:  P Faridi; M Dorvash; A W Purcell
Journal:  Clin Exp Immunol       Date:  2021-03-28       Impact factor: 4.330

6.  Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas.

Authors:  Devin Dersh; James D Phelan; Megan E Gumina; Boya Wang; Jesse H Arbuckle; Jaroslav Holly; Rigel J Kishton; Tovah E Markowitz; Mina O Seedhom; Nathan Fridlyand; George W Wright; Da Wei Huang; Michele Ceribelli; Craig J Thomas; Justin B Lack; Nicholas P Restifo; Thomas M Kristie; Louis M Staudt; Jonathan W Yewdell
Journal:  Immunity       Date:  2020-12-02       Impact factor: 31.745

7.  Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.

Authors:  Mathias Wilhelm; Daniel P Zolg; Michael Graber; Siegfried Gessulat; Tobias Schmidt; Karsten Schnatbaum; Celina Schwencke-Westphal; Philipp Seifert; Niklas de Andrade Krätzig; Johannes Zerweck; Tobias Knaute; Eva Bräunlein; Patroklos Samaras; Ludwig Lautenbacher; Susan Klaeger; Holger Wenschuh; Roland Rad; Bernard Delanghe; Andreas Huhmer; Steven A Carr; Karl R Clauser; Angela M Krackhardt; Ulf Reimer; Bernhard Kuster
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

Review 8.  Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy.

Authors:  Terufumi Kubo; Tomoyo Shinkawa; Yasuhiro Kikuchi; Kenji Murata; Takayuki Kanaseki; Tomohide Tsukahara; Yoshihiko Hirohashi; Toshihiko Torigoe
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

9.  Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides.

Authors:  Alessia Melacarne; Valentina Ferrari; Luca Tiraboschi; Michele Mishto; Juliane Liepe; Marina Aralla; Laura Marconato; Michela Lizier; Chiara Pozzi; Offer Zeira; Giuseppe Penna; Maria Rescigno
Journal:  Cell Rep       Date:  2021-07-06       Impact factor: 9.423

10.  Response: Commentary: An In Silico-In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients.

Authors:  Michele Mishto; Guillermo Rodriguez-Hernandez; Jacques Neefjes; Henning Urlaub; Juliane Liepe
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.